Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Diabetic Foot Ulcer
Interventions
DRUG

Pirfenidone with MODD

Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.

DRUG

Ketanserin

Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.

Trial Locations (2)

44340

Molecular Biology and Gene Therapy Institute, Guadalajara

Unknown

Hospital Valentín Gómez Farías, Zapopan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cell Pharma

OTHER

lead

University of Guadalajara

OTHER